A novel iron-chelating derivative of the neuroprotective peptide NAPVSIPQ shows superior antioxidant and antineurodegenerative capabilities

Journal of Medicinal Chemistry

Volumn 51, Issue 1, 2008, Pages 126-134

  Blat, Dan ^a   Weiner, Lev ^a   Youdim, Moussa B H ^b   Fridkin, Mati ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ASPARAGINYLALANYLPROLYLVALYLSERYLISOLEUCYLPROLYLGLUTAMINE DERIVATIVE; HYDROGEN PEROXIDE; HYDROXYL RADICAL; IRON CHELATING AGENT; NEUROPROTECTIVE AGENT; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG INDICATION; DRUG RESEARCH; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IRON CHELATION; LIPID PEROXIDATION; NERVE DEGENERATION; NEUROBLASTOMA CELL; NEUROPROTECTION; PEPTIDE SYNTHESIS;

ANIMALS; ANTIOXIDANTS; CELL LINE, TUMOR; CELL SURVIVAL; FERRIC COMPOUNDS; FERROUS COMPOUNDS; HUMANS; HYDROGEN PEROXIDE; HYDROXAMIC ACIDS; HYDROXYL RADICAL; IRON CHELATING AGENTS; LIPID PEROXIDATION; MALE; NEUROPROTECTIVE AGENTS; OLIGOPEPTIDES; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 37849020181     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070800l     Document Type: Article

References (61)

1. Barnham, K. J.; Masters, C. L.; Bush, A. I. Neurodegenerative Diseases and Oxidative Stress. Nat. Rev. Drug Discovery 2004, 3, 205-214.
2. Soto, C. Unfolding the Role of Protein Misfolding in Neurodegenerative Diseases. Nat. Rev. Neurosci. 2003, 4, 49-60.
3. Montine, T. J.; Neely, M. D.; Quinn, J. F.; Beal, M. F.; Markesbery, W. R.; Roberts, L. J.; Morrow, J. D. Lipid Peroxidation in Aging Brain and Alzheimer's Disease. Free Radical Biol. Med. 2002, 33, 620-626.
4. Dexter, D. T.; Carter, C. J.; Wells, F. R.; Javoy-Agid, F.; Agid, Y.; Lees, A.; Jenner, P.; Marsden, C. D. Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease. J. Neurochem. 1989, 52, 381-389.
5. Butterfield, D. A.; Lauderback, C. M. Lipid Peroxidation and Protein Oxidation in Alzheimer's Disease Brain: Potential Causes and Consequences Involving Amyloid Beta-Peptide-Associated Free Radical Oxidative Stress. Free Radical Biol. Med. 2002, 32, 1050-1060.
6. Gabbita, S. P.; Lovell, M. A.; Markesbery, W. R. Increased Nuclear DNA Oxidation in the Brain in Alzheimer's Disease. J. Neurochem. 1998, 71, 2034-2040.
7. Alam, Z. I.; Jenner, A.; Daniel, S. E.; Lees, A. J.; Cairns, N.; Marsden, C. D.; Jenner, P.; Halliwell, B. Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8-Hydroxyguanine Levels in Substantia Nigra. J. Neurochem. 1997, 69, 1196-1203.
8. Zecca, L.; Youdim, M. B.; Riederer, P.; Connor, J. R.; Crichton, R. R. Iron, Brain Ageing and Neurodegenerative Disorders. Nat. Rev. Neurosci. 2004, 5, 863-873.
9. Morita, A.; Kimura, M.; Itokawa, Y. The Effect of Aging on the Mineral Status of Female Mice. Biol. Trace Elem. Res. 1994, 42, 165-177.
10. Takahashi, S.; Takahashi, I.; Sato, H.; Kubota, Y.; Yoshida, S.; Muramatsu, Y. Age-Related Changes in the Concentrations of Major and Trace Elements in the Brain of Rats and Mice. Biol. Trace Elem. Res. 2001, 80, 145-158.
11. Lovell, M. A.; Robertson, J. D.; Teesdale, W. J.; Campbell, J. L.; Markesbery, W. R. Copper, Iron and Zinc in Alzheimer's Disease Senile Plaques. J. Neurol. Sci. 1998, 158, 47-52.
12. Smith, M. A.; Harris, P. L.; Sayre, L. M.; Perry, G. Iron Accumulation in Alzheimer Disease Is a Source of Redox-Generated Free Radicals. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 9866-9868.
13. Castellani, R. J.; Siedlak, S. L.; Perry, G.; Smith, M. A. Sequestration of Iron by Lewy Bodies in Parkinson's Disease. Acta. Neuropathology (Berlin) 2000, 100, 111-114.
14. Wardman, P.; Candeias, L. P. Fenton Chemistry: An Introduction. Radiat. Res. 1996, 145, 523-531.
15. Tabner, B. J.; Turnbull, S.; El-Agnaf, O. M.; Allsop, D. Formation of Hydrogen Peroxide and Hydroxyl Radicals from A(Beta) and Alpha-Synuclein as a Possible Mechanism of Cell Death in Alzheimer's Disease and Parkinson's Disease. Free Radical Biol. Med. 2002, 32, 1076-1083.
16. Huang, X.; Atwood, C. S.; Hartshorn, M. A.; Multhaup, G.; Goldstein, L. E.; Scarpa, R. C.; Cuajungco, M. P.; Gray, D. N.; Lim, J.; Moir, R. D.; Tanzi, R. E.; Bush, A. I. The A Beta Peptide of Alzheimer's Disease Directly Produces Hydrogen Peroxide through Metal Ion Reduction. Biochemistry 1999, 38, 7609-7616.
17. Turnbull, S.; Tabner, B. J.; El-Agnaf, O. M.; Moore, S.; Davies, Y.; Allsop, D. Alpha-Synuclein Implicated in Parkinson's Disease Catalyses the Formation of Hydrogen Peroxide in Vitro. Free Radical Biol. Med. 2001, 30, 1163-1170.
18. Mantyh, P. W.; Ghilardi, J. R.; Rogers, S.; DeMaster, E.; Allen, C. J.; Stimson, E. R.; Maggio, J. E. Aluminum, Iron, and Zinc Ions Promote Aggregation of Physiological Concentrations of Beta-Amyloid Peptide. J. Neurochem. 1993, 61, 1171-1174.
19. Hu, W. P.; Chang, G. L.; Chen, S. J.; Kuo, Y. M. Kinetic Analysis of Beta-Amyloid Peptide Aggregation Induced by Metal Ions Based on Surface Plasmon Resonance Biosensing. J. Neurosci. Methods. 2006, 154, 190-197.
20. Uversky, V. N.; Li, J.; Fink, A. L. Metal-Triggered Structural Transformations, Aggregation, and Fibrillation of Human Alpha-Synuclein. A Possible Molecular Link between Parkinson's Disease and Heavy Metal Exposure. J. Biol. Chem. 2001, 276, 44284-44296.
21. Rogers, J. T.; Randall, J. D.; Cahill, C. M.; Eder, P. S.; Huang, X.; Gunshin, H.; Leiter, L.; McPhee, J.; Sarang, S. S.; Utsuki, T.; Greig, N. H.; Lahiri, D. K.; Tanzi, R. E.; Bush, A. I.; Giordano, T.; Gullans, S. R. An Iron-Responsive Element Type II in the 5′-Untranslated Region of the Alzheimer's Amyloid Precursor Protein Transcript. J. Biol. Chem. 2002, 277, 45518-45528.
22. Ben-Shachar, D.; Eshel, G.; Finberg, J. P.; Youdim, M. B. The Iron Chelator Desferrioxamine (Desferal) Retards 6-Hydroxydopamine-Induced Degeneration of Nigrostriatal Dopamine Neurons. J Neurochem. 1991, 56, 1441-1444.
23. Lan, J.; Jiang, D. H. Desferrioxamine and Vitamin E Protect against Iron and MPTP-Induced Neurodegeneration in Mice. J. Neural Transm. 1997, 104, 469-481.
24. Kaur, D.; Yantiri, F.; Rajagopalan, S.; Kumar, J.; Mo, J. Q.; Boonplueang, R.; Viswanath, V.; Jacobs, R.; Yang, L.; Beal, M. F.; DiMonte, D.; Volitaskis, I.; Ellerby, L.; Cherny, R. A.; Bush, A. I.; Andersen, J. K. Genetic or Pharmacological Iron Chelation Prevents Mptp-Induced Neurotoxicity in Vivo: A Novel Therapy for Parkinson's Disease. Neuron 2003, 37, 899-909.
25. Cherny, R. A.; Atwood, C. S.; Xilinas, M. E.; Gray, D. N.; Jones, W. D.; McLean, C. A.; Barnham, K. J.; Volitakis, I.; Fraser, F. W.; Kim, Y.; Huang, X.; Goldstein, L. E.; Moir, R. D.; Lim, J. T.; Beyreuther, K.; Zheng, H.; Tanzi, R. E.; Masters, C. L.; Bush, A. I. Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits Beta-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice. Neuron 2001, 30, 665-676.
26. Whitnall, M.; Richardson, D. R. Iron: A New Target for Pharmacological Intervention in Neurodegenerative Diseases. Semin. Pediatr. Neurol. 2006, 13, 186-197.
27. Shachar, D. B.; Kahana, N.; Kampel, V.; Warshawsky, A.; Youdim, M. B. Neuroprotection by a Novel Brain Permeable Iron Chelator, Vk-28, against 6-Hydroxydopamine Lession in Rats. Neuropharmacology 2004, 46, 254-263.
28. Levites, Y.; Weinreb, O.; Maor, G.; Youdim, M. B.; Mandel, S. Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate Prevents N-Methyl-4-phenyl-1,2, 3,6-tetrahydropyridine-Induced Dopaminergic Neurodegeneration. J. Neurochem. 2001, 78, 1073-1082.
29. Reznichenko, L.; Amit, T.; Zheng, H.; Avramovich-Tirosh, Y.; Youdim, M. B.; Weinreb, O.; Mandel, S. Reduction of Iron-Regulated Amyloid Precursor Protein and Beta-Amyloid Peptide by (-)-Epigallocatechin-3-Gallate in Cell Cultures: Implications for Iron Chelation in Alzheimer's Disease. J. Neurochem. 2006, 97, 527-536.
30. Ashur-Fabian, O.; Segal-Ruder, Y.; Skutelsky, E.; Brenneman, D. E.; Steingart, R. A.; Giladi, E.; Gozes, I. The Neuroprotective Peptide NAP Inhibits the Aggregation of the Beta-Amyloid Peptide. Peptides 2003, 24, 1413-1423.
31. Gozes, I.; Steingart, R. A.; Spier, A. D. NAP Mechanisms of Neuroprotection. J. Mol. Neurosci. 2004, 24, 67-72.
32. Bassan, M.; Zamostiano, R.; Davidson, A.; Pinhasov, A.; Giladi, E.; Perl, O.; Bassan, H.; Blat, C.; Gibney, G.; Glazner, G.; Brenneman, D. E.; Gozes, I. Complete Sequence of a Novel Protein Containing a Femtomolar-Activity-Dependent Neuroprotective Peptide. J. Neurochem. 1999, 72, 1283-1293.
33. Steingart, R. A.; Solomon, B.; Brenneman, D. E.; Fridkin, M.; Gozes, I. VIP and Peptides Related to Activity-Dependent Neurotrophic Factor Protect PC12 Cells against Oxidative Stress. J. Mol. Neurosci. 2000, 15, 137-145.
34. Offen, D.; Sherki, Y.; Melamed, E.; Fridkin, M.; Brenneman, D. E.; Gozes, I. Vasoactive Intestinal Peptide (VIP) Prevents Neurotoxicity in Neuronal Cultures: Relevance to Neuroprotection in Parkinson's Disease. Brain Res. 2000, 854, 257-262.
35. Gozes, I.; Giladi, E.; Pinhasov, A.; Bardea, A.; Brenneman, D. E. Activity-Dependent Neurotrophic Factor: Intranasal Administration of Femtomolar-Acting Peptides Improve Performance in a Water Maze. J. Pharmacol. Exp. Ther. 2000, 293, 1091-1098.
36. Leker, R. R.; Teichner, A.; Grigoriadis, N.; Ovadia, H.; Brenneman, D. E.; Fridkin, M.; Giladi, E.; Romano, J.; Gozes, I. NAP, a Femtomolar-Acting Peptide, Protects the Brain against Ischemic Injury by Reducing Apoptotic Death. Stroke 2002, 33, 1085-1092.
37. Youdim, M. B.; Fridkin, M.; Zheng, H. Bifunctional Drug Derivatives of MAO-B Inhibitor Rasagiline and Iron Chelator Vk-28 as a More Effective Approach to Treatment of Brain Ageing and Ageing Neurodegenerative Diseases. Mech. Ageing Dev. 2005, 126, 317-326.
38. Yogev-Falach, M.; Bar-Am, O.; Amit, T.; Weinreb, O.; Youdim, M. B. A Multifunctional, Neuroprotective Drug, Ladostigil (Tv3326), Regulates Holo-APP Translation and Processing. FASEB J. 2006, 20, 2177-2179.
39. Zheng, H.; Blat, D.; Fridkin, M.; Novel. Neuroprotective Neurotrophic NAP Analogs Targeting Metal Toxicity and Oxidative Stress: Potential Candidates for the Control of Neurodegenerative Diseases. J. Neural Transm., Suppl. 2006, 71, 163-172.
40. Bergeron, R. J.; Wiegand, J.; McManis, J. S.; Perumal, P. T. Synthesis and Biological Evaluation of Hydroxamate-Based Iron Chelators. J. Med. Chem. 1991, 34, 3182-3187.
41. Ye, Y.; Liu, M.; Kao, J. L.; Marshall, G. R. Peptide-Bond Modification for Metal Coordination: Peptides Containing Two Hydroxamate Groups. Biopolymers 2003, 71, 489-515.
42. Gaeta, A.; Hider, R. C. The Crucial Role of Metal Ions in Neurodegeneration: The Basis for a Promising Therapeutic Strategy. Br. J. Pharmacol. 2005, 146, 1041-1059.
43. Harris, D. C.; Aisen, P. Facilitation of Fe(II) Autoxidation by Fe(III) Complexing Agents. Biochim. Biophys. Acta 1973, 329, 156-158.
44. Farkas, E.; Enyedy, E. A.; Zekany, L.; Deak, G. Interaction between Iron(II) and Hydroxamic Acids: Oxidation of Iron(II) to Iron(III) by Desferrioxamine B under Anaerobic Conditions. J. Inorg. Biochem. 2001, 83, 107-114.
45. Wilkemeyer, M. F.; Chen, S. Y.; Menkari, C. E.; Brenneman, D. E.; Sulik, K. K.; Charness, M. E. Differential Effects of Ethanol Antagonism and Neuroprotection in Peptide Fragment NAPVSIPQ Prevention of Ethanol-Induced Developmental Toxicity. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 8543-8548.
46. Carter, P. Spectrophotometric Determination of Serum Iron at the Submicrogram Level with a New Reagent (Ferrozine). Anal. Biochem. 1971, 40, 450-458.
47. Anderegg, G.; L'Eplattenier, F.; Schwarzenbach, G. Hydroxamate Complexes. III. Iron(III) Exchange between Sideramines and Complexones. A Discussion of the Formation Constants of the Hydroxamate Complexes. Helv. Chim. Acta 1963, 46, 1409-1422.
48. Spasojevic, I.; Crumbliss, A. L. pH Induced Active ("Uphill") Liquid Membrane Transport of Ferrioxamine B by the Ionizable Ionophore Lasalocid. Inorg. Chem. 1999, 38, 3248-3250.
49. Boukhalfa, H.; Crumbliss, A. L. Chemical Aspects of Siderophore Mediated Iron Transport. BioMetals 2002, 15, 325-339.
50. Kretchmar Nguyen, S. A.; Craig, A.; Raymond, K. N. Transferrin: The Role of Conformational Changes in Iron Removal by Chelators. J. Am. Chem. Soc. 1993, 115, 6758-6764.
51. Singh, S.; Khodr, H.; Taylor, M. I.; Hider, R. C. Therapeutic Iron Chelators and Their Potential Side-Effects. Biochem. Soc. Symp. 1995, 61, 127-137.
52. Graf, E.; Mahoney, J. R.; Bryant, R. G.; Eaton, J. W. Iron-Catalyzed Hydroxyl Radical Formation. Stringent Requirement for Free Iron Coordination Site. J. Biol. Chem. 1984, 259, 3620-3624.
53. Snyrychova, I.; Pospisil, P.; Naus, J. The Effect of Metal Chelators on the Production of Hydroxyl Radicals in Thylakoids. Photosynth. Res. 2006, 88, 323-329.
54. Buettner, G. R. Spin Trapping: ESR Parameters of Spin Adducts. Free Radical Biol. Med. 1987, 3, 259-303.
55. Beni-Adani, L.; Gozes, I.; Cohen, Y.; Assaf, Y.; Steingart, R. A.; Brenneman, D. E.; Eizenberg, O.; Trembolver, V.; Shohami, E. A Peptide Derived from Activity-Dependent Neuroprotective Protein (ADNP) Ameliorates Injury Response in Closed Head Injury in Mice. J. Pharmacol. Exp. Ther. 2001, 296, 57-63.
56. Ashur-Fabian, O.; Giladi, E.; Furman, S.; Steingart, R. A.; Wollman, Y.; Fridkin, M.; Brenneman, D. E.; Gozes, I. Vasoactive Intestinal Peptide and Related Molecules Induce Nitrite Accumulation in the Extracellular Milieu of Rat Cerebral Cortical Cultures. Neurosci. Lett. 2001, 307, 167-170.
57. Gozes, I.; Divinski, I. The Femtomolar-Acting NAP Interacts with Microtubules: Novel Aspects of Astrocyte Protection. J. Alzheimer's Dis. 2004, 6, S37-S41.
58. Divinski, I.; Holtser-Cochav, M.; Vulih-Schultzman, I.; Steingart, R. A.; Gozes, I. Peptide Neuroprotection through Specific Interaction with Brain Tubulin. J. Neurochem. 2006, 98, 973-984.
59. Atherton, E.; Sheppard, R. C. Solid Phase Peptide Synthesis: A Practical Approach; IRL Press: Oxford, U.K., 1989.
60. Gassen, M.; Glinka, Y.; Pinchasi, B.; Youdim, M. B. Apomorphine Is a Highly Potent Free Radical Scavenger in Rat Brain Mitochondrial Fraction. Eur. J. Pharmacol. 1996, 308, 219-225.
61. Hansen, M. B.; Nielsen, S. E.; Berg, K. Re-Examination and Further Development of a Precise and Rapid Dye Method for Measuring Cell Growth/Cell Kill. J. Immunol. Methods 1989, 119, 203-210.